A Professional Service Provider for the Pharma Industry
There have been several articles on the China Pharma market recently, its development pipeline and the changes to the regulatory environment [1], [2], [3]. They paint a picture of R&D in transition; a provider of services becoming an innovator, a maturing pharma landscape that is increasingly more efficient and business-oriented, with Continue reading The Economist On China Pharma Going Global
In 2024, the ECDC published a detailed review of flu vaccine studies [1]. In particular, the report examined published trials of newer flu vaccines. As is well known, the older vaccines provide significant protection, but efficacy is diminished in certain populations. Especially the elderly are at an increased risk of Continue reading INFLUENZA VACCINATION IN THE ELDERLY
There are studies that are bound to succeed, and those that are likely to fail. A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds. We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study